SCARB1 and SOAT1, despite evidence from metabolic disease models indicating that modulation of transcytosis or cholesterol esterification can alter intracellular lipid handling, currently lack any marketed therapeutics. This evidence concerns the gene SOAT1 and metabolic disease.